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Anticoagulation for patients with venous thrombosis For patients who have suffered thrombosis in situ
has changed radically in recent years, with a move the evidence about long-term anticoagulation is poor.
from initial inpatient treatment using intravenous un- Not only is there sparse information about the long-
fractionated heparin (UFH) to subcutaneous low mo- term fate of these patients, but separating them from
lecular weight heparin (LMWH) – often on an those with an index event of acute embolic ischaemia
outpatient basis. This change has been based on sound may be difficult. There is some evidence from a survey
theory and convincing evidence from clinical trials.1 by the Vascular Surgical Society of Great Britain and
However, there are no good data about using sub- Ireland that long-term oral anticoagulation may reduce
cutaneous LMWH in arterial problems, and most vas- the occurrence of further thrombotic events,5 and it
cular surgeons continue to use intravenous heparin seems reasonable to anticoagulate these patients. In
this group, too, the use of subcutaneous LMWH canthroughout their treatment of arterial disease. This
paradox invites comment, and also provides a basis be considered during the interval between treatment
of the acute problem (by thrombolysis, surgery, orfor considering some other aspects of anticoagulation
for patients with arterial disease. conservative measures) and the achievement of ad-
equate oral anticoagulation.Patients presenting with acute limb ischaemia are
perhaps the most obvious group requiring anti- An added advantage of using LMWH for post-
operative patients is that outpatient administrationcoagulation. When acute ischaemia is diagnosed a
bolus of UFH, followed by an intravenous infusion, may reduce the need to achieve target prothrombin
times quickly (in order to discontinue intravenousprovides immediate anticoagulation, which can be
discontinued to provide rapid restoration of clotting UFH and discharge the patient from hospital). This
may be a particular advantage in frail, elderly patients,at the time of any intervention (the half life of UFH is
about 90 min). After embolectomy (or thrombolysis) some of whom are unduly susceptible to standard
doses of warfarin; and in patients for whom excessivepatients with embolism from atrial fibrillation are
best anticoagulated in the long term.2–4 It is usual anticoagulation poses particular risks.
Patients with bypass grafts are another group forto continue intravenous UFH for a few days after
embolectomy while oral anticoagulants are started and whom anticoagulants are sometimes used, but practice
varies considerably.6 The main reasons that they aremonitored, with the aim of preventing early recurrence
of embolism. In these circumstances there would seem used by some surgeons include high-risk bypasses7 (for
example, distal bypasses using synthetic material,8 orto be practical advantages in the use of subcutaneous
LMWH in full anticoagulant doses while the pro- any distal graft into very poor runoff) and after sec-
ondary procedures done to restore graft patency. Thethrombin time is stabilised on oral anticoagulants.
Daily subcutaneous injections of LMWH replace the evidence for oral anticoagulation after infrainguinal
vein grafting9 has been strengthened recently by theneed for an intravenous syringe pump, so enabling
early discharge from hospital. Postoperatively there results of the Dutch Bypass Oral anticoagulants or As-
pirin (BOA) Study,10 which have shown a lower rate ofis no special need for the potential to discontinue
anticoagulation rapidly, which is one of the reasons graft occlusions and ischaemic events using anti-
coagulants compared with aspirin. It is important tofor using intravenous UFH before operation.
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note that this result applied only to vein bypass grafts: requirement for long-term follow-up. Definite answers
aspirin was better for the prevention of occlusion of may therefore be elusive, but there is nevertheless a case
non-venous grafts in the BOA study. for vascular surgeons reappraising and debating their
For primary prevention of graft occlusion in the use of anticoagulants in the light of current knowledge.
longer term, simply starting oral anticoagulants a day
or two after surgery may be regarded as sufficient,
but there may be a case for using LMWH during the
first few days after operation, as described above.
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